Flu tests from R-Biopharm also detect new virus variants
Darmstadt, November 25, 2022 – The flu season has begun and different virus variants are also circulating in Germany. With the flu tests from biotechnology company R-Biopharm, patients quickly have certainty: Its RIDA®GENE Flu assays also reliably detect the two novel variants. The company made the announcement with regard to influenza A H1N1pdm09, which is circulating primarily in the United Kingdom, and the H3N2 subtype, which was rampant in Denmark in the spring and is currently dominating influenza activity in Germany.
"Mutations in the target gene (MP gene) can affect the diagnostic performance of influenza screening assays, producing false-negative test results," explains Dr. Andreas Simons, Head of Product Management at R-Biopharm. " Alignments of the detection systems we used with the described sequences of the two novel virus variants showed no mismatches. Their reliable detection is not affected by the described mutations."
This means laboratories can continue to reliably confirm or rule out influenza infections using R-Biopharm's RIDA®GENE (PG0505, PG0545, PG6825) assays. The tests are multiplex real-time RT-PCR for the direct qualitative detection of influenza viruses.
Head of Corporate Brand Communication
An der neuen Bergstraße 17
Phone: 0 61 51 - 81 02-538
Mobile: 0 160 - 55 273 60
Fax: 0 61 51 - 81 02-40
About R-Biopharm AG
R-Biopharm AG, located in Darmstadt, is one of Germany's leading biotechnology companies. Founded in 1988, the company is family-run in the second generation and considers itself as a pioneer for health and quality of life. Its aspiration: to provide the highest possible precision, safety, clarity and certainty in prevention, therapy and healing. To this end, R-Biopharm develops technologies, products and solutions for Clinical Diagnostics, Nutrition Care and Food and Feed Analytics – and does so in internationally recognized top quality. R-Biopharm is the world market leader for test systems in the field of allergen analysis.
R-Biopharm unites research, development and sales under one roof in order to respond to ever new challenges with agile processes and to accompany the steadily growing world population into a new health era. The company is represented in more than 120 countries – through 29 subsidiaries and 120 distributors. It employs around 1,400 people worldwide (690 at its headquarters in Darmstadt) and was repeatedly recognized with the "Sustainability Award" for sustainable and profitable growth.
Subscribe to releases from R-Biopharm AG
Subscribe to all the latest releases from R-Biopharm AG by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from R-Biopharm AG
R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories19.7.2022 08:00:00 CEST | Pressemeddelelse
Darmstadt, July 19, 2022 – As a fully integrated solution, the new and completely automated RIDA®UNITY system combines sample extraction, PCR setup, real-time PCR and result evaluation in a common workflow. The biotechnology company R-Biopharm AG announced today that it has received the CE mark and will begin selling the new, fully automated RIDA®UNITY system for molecular detection of infectious diseases throughout Europe. "With the RIDA®UNITY system, R-Biopharm is purposefully taking the path from a provider of individual solutions to a system provider in the field of molecular diagnostics," stated Christian Dreher, CEO of R-Biopharm. "We are very happy to make this system solution available to all molecular biology laboratories throughout Europe." Unique combination of different tools The RIDA®UNITY system combines the various steps in the analysis of patient samples into an integrated workflow – nucleic acid extraction, PCR setup, subsequent real-time PCR and the evaluation of the
R-Biopharm is IVDR certified30.6.2022 11:30:00 CEST | Press release
The quality management system of the biotechnology company complies with the European in-vitro Diagnostic Regulation (IVDR)
R-Biopharm acquires Australian lab equipment manufacturer and molecular biology multiplex specialist AusDiagnostics7.6.2022 10:00:00 CEST | Press release
Gaining new market segments in clinical diagnostics – globally unique position as system supplier in laboratory diagnostics sector
R-Biopharm announces test to detect monkeypox virus1.6.2022 13:27:17 CEST | Press release
Test for research purposes available soon R-Biopharm AG, a leading and globally operating biotechnology company based in Germany, will soon launch a test for the detection of monkeypox virus. The real-time PCR test, developed for research purposes (RUO), shall contribute to track and control the epidemiological spread of the virus. The product is expected to be available in approximately two to three weeks under the name RIDA®GENE Monkeypox Virus RUO (part number PG4915RUO). Like the test for the detection of the SARS-CoV-2 virus, which was the first to be launched by a German company for research purposes in February 2020 and was officially approved for the diagnosis of SARS-CoV-2 in the fall of 2020 with the CE mark, the real-time PCR test for the detection of monkeypox virus will also be usable on all common real-time PCR instruments. The uniform RIDA®GENE design also allows users to run this test together with other RIDA®GENE products. "R-Biopharm cares about the common good," says
R-Biopharm receives approval of COVID-19 test in the UK under CTDA legislation7.12.2021 13:35:22 CET | Press release
R-Biopharm, an international specialist in clinical diagnostics, announces that the company’s RIDA®GENE Flu & SARS-CoV-2 multiplex test (PG6825) has been approved in the UK under the UK Health Security Agency’s Medical Devices (Coronavirus Test Device Approvals) Regulations 2021 (“CTDA”). R-Biopharm will now work to resume the sale of the product in the UK. RIDA®GENE Flu & SARS-CoV-2 test is a multiplex real-time RT-PCR for the direct qualitative detection and differentiation of Flu A/Flu B and coronavirus (SARS-CoV-2) RNA in human nasal/throat swabs from persons with signs and symptoms of respiratory infection. It is intended for professional use for example in hospital laboratories, reference laboratories, private laboratories, or public laboratories. The RIDA®GENE Flu & SARS-CoV-2 multiplex test targets the M gene/NP1 gene of the virus for Influenza A/B and the E gene and RdRpgene in all currently known variants and mutations of the COVID 19 virus. Only validated products, or produc